Cytotoxic antineoplastic drugs (ADs) pose occupational risk and therefore require safe handling practices. We created, optimised, and validated an innovative monitoring protocol for simultaneously assessing 21 ADs in the healthcare environment, and also proposed surface exposure levels (SELs) to facilitate the interpretation of monitoring results, as there are currently no occupational exposure limits for ADs. The environmental AD monitoring data were collected in nine Italian hospitals between 2008 and 2017 and include 74,565 measurements in 4,814 wipe samples. Excellent overall recovery and sensitivity of the analytical methods along with innovative desorption automation make this protocol useful for routine monitoring. AD contamination was found in 3,081 measurements, confirming potential exposure in healthcare workers. Samples taken at the beginning and the end of work shifts, allowed to calculate 75 th and 90 th percentile values for each ADs both in preparation and administration units and we created a traffic-light colour-coding system to facilitate interpretation of the findings. The introduction of SELs will provide a solid basis for improving occupational safety and focusing on contamination control.
According to the World Cancer Research Fund International (1), the age-standardised rate for all cancers in men and women combined was 182 people per 100,000 in 2012, and in 2035, there will be around 24 million new cases of cancer around the world. Pacific Asia has been identified as a rather lucrative region for the anti-cancer drug market owing to the rising awareness of the availability of advanced therapies (2) . In China, nearly four million new tumour cases appear every year, and by 2021, the total output of cytotoxic drugs is expected to reach 1,000 tonnes (3) with an estimated compound annual growth rate between 7.1 % and 7.4 % of the global market (4, 5) . Furthermore, antineoplastic drugs (ADs) like cyclophosphamide (CP) and methotrexate (MT) have proved beneficial against nonmalignant diseases too, such as rheumatoid arthritis and multiple sclerosis, and their use is expected only to increase.
The National Institute for Occupational Safety and Health (NIOSH) (6) has recently released its updated list of hazardous drugs and has estimated that millions of healthcare workers -those who prepare and administer these medications to patients with cancer and other conditions -run the risk of exposure to these hazardous drugs at their workplace. The list includes chemotherapy drugs, many of which are mutagenic and carcinogenic (7).
Concerns about occupational exposure to ADs were first expressed in the 1970s, and studies continue to evidence healthcare worker susceptibility. Ratner et al. (8) reported higher risk of breast cancer and reproductive health effects in nurses employed in oncology units. Hall et al. (9) show that about 75,000 Canadians -0.42 % of the total workforce -are occupationally exposed to ADs, 75 % of whom are women. In Italy, of the 331 oncology wards surveyed, 256 have a centralised antineoplastic drug (AD) preparation unit, employing a total of 7,000 operators (10) . As the usage and number of these drugs increase, so do opportunities for exposures (11) .
The basic occupational health approach to minimising exposure risks combines several industrial hygiene control methods in a specific order or hierarchy. One of these methods, environmental monitoring, enables us to pinpoint contamination trends, identify corrective measures, and increase workers' awareness. In the case of cytotoxic ADs, monitoring surface contamination in hospital environments usually involves wipe tests as a simple way to indirectly assess dermal occupational exposure (12) . However, most of the monitoring (13) (14) (15) (16) (17) (18) (19) (20) is focused on no more than five ADs among the following drugs: CP, MT, iphosfamide (IP), paclitaxel (PTX), doxorubicin (DXR), 5-fluorouracyl (5-FU), docetaxel (DTX), epirubicin (EPI), and gemcitabine (GEM). Only a few (21) (22) (23) In the present work we propose our innovative surface monitoring protocol for multiple classes of ADs, while, at the same time, automating and standardising the procedure to considerably decrease the time needed for sample preparation and analysis. In addition, we propose surface exposure levels (SELs) for twenty-one ADs.
MATERIALS AND METHODS

Experimental design
To evaluate AD contamination of work surfaces, we evaluated 4,814 wipes (Table 1 ) from nine hospitals located in the northern, central, and southern Italy from 2008 to 2017. Sampling included 9 cytostatic preparation and 17 administration units. The volume of AD administrations ranged from 18,011 to 48,086 per hospital per year. Hospital programs followed the Italian guidelines (G.U. 236, 7.10.1999), specifically: i) staff were trained and re-trained in safety equipment and maintenance, research updates, and emergency care); ii) closed system devices were used for drug transfer between preparation and administration units to prevent any escape of hazardous drugs (ChemoClave, ICU Medical Inc., San Clemente, USA; CareFusion, Becton Dickinson, Franklin Lakes, USA; Cyto-Set, B-Braun, Milan, Italy); and iii) specific cleaning products were utilised for floors (0.2 % Marseille soap solution, 0.115 % sodium hypochlorite, and 70 % ethanol, in this order) and for small surfaces (Alcavis Bleach-Wipe 1:50, Angelini Pharma Inc., Gaithersburg, MD, USA) such as the laminar flow hoods, syringe pumps, and phone handsets. In one hospital, hazardous drugs were reconstituted and prepared with a Diana Hazardous Drug Compounding System (ICU Medical Inc., San Clemente, CA, USA), a needle-free, user-controlled automated compounding system. The centralised AD preparation units, protected by an anteroom, were all equipped with four IIA2-class biological safety cabinets.
The levels of CP, 5-FU, IP, MT, GEM, EPI, PTX, DTX, VNC, VNB, ETP, CTB, IRT, dacarbazine (DC), mitomycin C (MITC), doxorubicin (DXR), topotecan (TPT), melphalan (MP), idarubicine (IDC), fotemustine (FTM), and Pt -as a marker of cis -, carbo-, and oxaliplatin -were all measured in each wipe sample (altogether 74,565 measurements). Trophosphamide, daunorubicin, cephalomannine and 5-chlorouracil were chosen as internal standards for liquid chromatography (LC)-triple quadrupole mass spectrometry (MS/MS) quantification.
Wipe sampling
Wipe samples were collected from the preparation and administration units at the beginning (B-WS) and at the end of the work shift (E-WS). When possible, the samples were also collected in the middle of the shift. We used a standardised kit, which comprises all the necessary tools ( Figure 1 ): 5x5 cm, 3-layer nonwoven fabric wipes (Cat. No. 26015Y, 6-layer Luxor-Net, STS Medical Group Luigi Salvadori, Scandicci, Italy) wetted with 500 µL of an equimolar water/methanol solution, stored in a wipe cartridge kit (WCK) (Figure 2 ) developed by Chromline (Prato, Italy), assembled with 0.2 µm GHP Acrodisc 13 mm filters (Cat. No. PN4567, Pall Corporation, New York, NY, USA) and connected to a 2 mL vial by a joint, tweezers with a joint for disposable pipette tips, as well as a precise instruction manual with photos and a video on the correct technique for obtaining wipe samples. Dugheri 
B-WS = before the work shift; E-WS = end of the work shift; ⅀ = sum of B-WS and E-WS values; N/A = not-applicable
placed inside the WCK in off-line mode using Automated Wipe Desorption (Chromline, Prato, Italy) installed on a Flex GC autosampler (EST Analytical, Fairfield, USA) equipped with two 50-position WCK trays and a 2.5 mL headspace syringe.
Analytical procedures
The twenty ADs were quantitated with a LC-MS/MS (Alliance e2695/Quattro Micro API, Waters, Milford, USA) using fragment ions produced via collision-induced fragmentation. Table 1 ) an area of 20x20 cm was wiped with tweezers in three standard directions (down, left, and right), whereas the surfaces smaller than 20x20 cm were wiped in the same way but the exact area was recorded.
The wipe with 1.8 mL of equimolar water/methanol solution containing 20 ng mL -1 of internal standards, was Five replicates for every standard were analysed, and the peak area ratio from each analyte and internal standard used to obtain the response factor plot. The slopes (m) and intercepts (b) of the calibration lines were estimated with the least-square linear regression analysis, using the following formula: y=mx+b where y is the ratio between the chromatographic area of the analyte and its internal standard, and x is the concentration of the analyte.
Figure 1 Wipe sampling kit: 1) wheel-trolley; 2) wipe cartridge kit (WCK) used for automatic desorption, preassembled with 5x5 cm, 3-layer nonwoven fabric; 3) 50-position WCK trays; 4) personal computer; 5) barcode reader; 6) CD instruction manual with photos and a video on the correct technique for obtaining wipe samples; 7) tweezer tip waste container) 8) tweezer tips; 9) 5x5 cm, 3-layer nonwoven fabric and tweezers with disposable tips
The limit of detection (LOD) was calculated according to the formula:
where SE b is the standard error of the intercept. The lower limit of quantification (LOQ) was then estimated in the same way using 10SE b , which corresponds to 3.3 LOD.
The precision of the assay (as a coefficient of variation, CV %) was estimated both as within-session and as intersession repeatability.
Within-session accuracy was evaluated by recoveries (reported as the percentage ratio between the measured and the nominal concentrations) at all concentrations used for the calibration plot (Table 2 ). These accuracy values were 
Accuracy and precision (%)
Within-session accuracy ) level quality control samples (QCs) were prepared and processed in every analytical session from a fresh solution with 21 ADs with internal standards to ensure the intra-and inter-day repeatability of reported results.
Validation study
The wiping recoveries of each AD were evaluated in terms of the percentage of removal efficiency from spiked surfaces. To do that, we quantified additional wipe samples taken from stainless steel, smooth (non-porous polycarbonate) and less smooth (polyvinyl chloride flooring), 20x20 cm brand new plates spiked to 20 ng (50 pg cm -2 ) and 100 ng (250 pg cm -2 ) of AD. Spiked wipe sample stability was tested at 4 °C from 4 to 24 h.
The desorption efficiencies were calculated as the percentage of response decline between the spiked wipes and the nominal AD solution analysed.
We also established the MS matrix effects in six replicates for each AD in terms of mean relative ionisation recovery for the analytes, calculated as the percentage of response decline between the analytes spiked into the eluate, obtained after extracting the blank wipe, and the analytes injected directly into the mobile phase.
The obtained data management were processed with the Stata data analysis and statistical software (StataCorp LLC, College Station, TX, USA).
RESULTS
Wiping and desorption
Our wiping procedure, with tweezers instead of a new pair of gloves as other authors do, reduced the sampling time (15 s per wiping), cost (as the price of the replaceable tweezer tips is much lower than that of gloves), and the risk of contamination, and the recoveries were over 75 % ( Table  2 ). The full insertion of the wipes into the holder and automation ensured desorption efficiencies close to 100 % for all ADs. The filling speed for the 2.5 mL syringe was set to 30 µL s -1 .
Analyses
Analytical curves were linear over the entire concentration range, with correlation coefficients (r 2 ) above 0.992 for all tested compounds. As the intra-and inter-day variability for all compounds ranged from 0.9-6.8 %, the average accuracy and inter-day precision were within the acceptable range. The LOQs for wipe ADs were between 0.06 and 3.49 ng wipe -1 ( Table 2) .
Data distribution
Of the 4,814 wipes taken 1,583 (604 in preparation units and 979 in administration units) were ≥LOQ (33 %). Of these, 775 were taken before and 808 after the work shift. Table 3 shows that of the 74,565 measurements, positive were 3,081 (1399 in preparation units and 1682 in administration units) or 4.1 %. Positive measurements for at least one AD before and after the work shift were 1,399 and 1,682, respectively. Most of them were determined on samples taken from "other surfaces" (waste containers, personal computers, support surfaces, intercoms, phones, and chairs), followed by the floors (23.2 %), laminar flow hoods (19.1 %), door handles (16.7 %), and what is referred to as "the bed area" (the bed, armchairs, drip shaft, and syringe pump) (9.8 %).
The six most frequently detected substances were CP (17.2 % of all CP measurements were positive), IP (15.4 % of all IP measurements were positive), GEM (8.6 %), Pt (5.4 %), and 5-FU (4.4 %), and PTX (4.1 %). Table 4 shows the number of measurements ≥LOQ as well as ranges by ADs.
Surface exposure levels
Because the values obtained showed a strongly skewed distribution, we decided to classify the data by the 90 th and the 75 th percentile instead of using normal distribution parameters. Table 5 shows the proposed limit surface exposure levels (SELs) for CP, IP, GEM, PTX, 5-FU, and Pt, expressed in pg cm -2 and derived from the percentiles of contamination levels for different categories of surfaces. Dugheri 
B-WS = before the work shift; E-WS = end of the work shift; ⅀ = sum of B-WS and E-WS values; N/A = not-applicable
These limits were actually adopted by all the nine participating hospital pharmacies and administration units for good hygiene practice. For all other ADs, the analysed 50 th , 75 th , and 90 th percentiles were lower than our LOQs.
DISCUSSION
Current analytical methods for biological monitoring are not sensitive or specific enough for ADs (12, 29, 30) . With modern ventilation resources at hand AD inhalation has become controlled and air sampling will soon be useless, which begs the question: which new validated environmental monitoring method will replace it. We recommend the wipe test, a method widely used by industrial hygienists and currently the only one able to detect ADs at levels as low as pg cm -2 . The actual risk to healthcare workers depends on AD toxicity and how these drugs enter the body; this should guide its handling protocols. In general, dermal absorption is more likely to occur with drugs with a molecular weight of <500 Da and less likely for those >1000 Da (31) (32) (33) (34) . The Occupational Safety and Health Administration (35) , United States Pharmacopeia (36) and the European Parliament Policy Recommendation (37) all suggest adopting an environmental monitoring program for ADs and using tools that facilitate easy interpretation of these results. Our procedure, as outlined in this paper, both monitors AD contamination of healthcare environment and reliably measures cleaning effectiveness and worker adherence to protocols.
The development of chromatographic methods for simultaneous analysis of polar and non-polar compounds has piqued the interest of the international scientific community (38) , including our research group. More specifically, some authors (13) (14) (15) 21) have proposed LC methods for 5-FU resolution via a C18 stationary phase combining hydrophobic and polar selectivity. Since our goal was to analyse as many ADs as possible at the same time, given that cancer treatments often include more than one cytotoxic drug and that this increases the probability of having at least one positive finding, we preferred to use two LC columns: one for hydrophobic cytostatic drugs and one for the hydrophilic ones. The former employs Atlantis T3 columns: silica-based, reversed-phase C18 columns that provide balanced retention of low-polar and hydrophobic molecules. Their T3 bonding utilises a trifunctional C18 alkyl phase with a ligand density that promotes polar compound retention and aqueous mobile phase compatibility. The second, utilises the SeQuant ZIC-hydrophilic interaction liquid chromatography (HILIC) to separate polar and hydrophilic compounds, and its high-performance, No governmental industrial hygiene association has yet set exposure limits for ADs since no safe exposure levels are known. Instead, the most commonly applied principle is "As Low As Reasonably Achievable" (ALARA), but interventions to reduce exposure as much as possible cannot be verified without quantitative evidence of environmental contamination. Perhaps the only environment where AD exposure can be monitored and limited is the workplace, and it is therefore imperative to do that. Furthermore, in agreement with Kromhout (40) , we strongly support quantitative assessment of AD exposure, as it ensures better accuracy of exposure estimates in occupational and domestic settings.
Ubiquitous environmental contamination with ADs is the consequence of their massive use. There is hardly a hospital not handling them, which inevitably leads to the contamination of drug containers and cross-contamination of cytotoxic drug vials (41) (42) (43) (44) . Furthermore, patients carry contamination home (45) , and eventually it reaches water (46) . The SELs we propose take into account different aspects of AD contamination that may occur in the healthcare environment: from contamination with pure drug in the preparation units to contamination with its diluted and biological (e.g. urine, saliva, sweat) forms in the administration units at the beginning and end of the work shift (i. e. when the workplace is expected to be clean and when it is not). Their purpose is to verify worker compliance with procedures, cleaning efficacy, and persistence of pollution over time. Our SELs are in line with the TGVs proposed by Böhlandt and Schierl (26) for 5-FU and Pt, the HGVs indicated by Hedmer and Wohlfart (27) for CP and IP, and with the cytotoxic-independent target value of 100 pg cm -2 proposed by Kiffmeyer et al. (22) , based on the 90 th percentile of the results.
We have therefore created a traffic-light colour-coding system for 21 ADs, where values between the LOQ and the 75 th percentile are coloured green, between the 75 th and the percentile red th percentile amber, and above the 90 th percentile red for user-friendly monitoring in healthcare environment at the beginning and at the end of the work shift. Table 6 illustrates the colour-coding system used by an AD pharmacy preparation unit in monitoring reports.
They will help in interpreting monitoring results, that is, until official threshold limits have been defined. In addition, this could facilitate comparison with other countries in order to extend the database and identify the best practices for handling drugs under different workplace conditions.
As for the wipe-sampling approach described in this study, we believe it can also be applied to other relevant substances, such as monoclonal antibodies and antibiotics on NIOSH's recent list of hazardous drugs.
